Phoenix Molecular Imaging 

Call Us:  480.881.5621

   The results of our large-scale experience with C11-Acetate were published in the January 2017 edition of the American Journal of Nuclear Medicine and Molecular Imaging.  The primary findings from the publication are that C11-Acetate PET/CT imaging demonstrates a very high detection rate for Prostate cancer recurrence (88%) and that both the PSA level and rate of PSA rise have an influence on the detection rate. C11-Acetate imaging was able to find early local or local-regional disease recurrence in a large number of men, which paved the way to additional individualized treatment options. Through support of the foundation (AMIFund.org), we are happy to be able to make this article widely available to the medical community and to the public via an open access journal  -  http://www.ajnmmi.us/files/ajnmmi0041325.pdf. 

   This core work is now being presented at various professional medical meetings and prostate cancer support symposium. 

   A joint publication with the Urological Team at the University of Southern California has been published in the January 2017 edition of the British Journal of Urology. In this study, we used C11-Acetate PET/CT imaging to help select and guide robotic lymph node dissection in Prostate Cancer recurrence. This work is part of multiple ongoing research studies exploring C11-Acetate imaging guided treatment options for those with cancer spread limited to the lymph nodes - http://onlinelibrary.wiley.com/doi/10.1111/bju.13741/full